Our Services
Others
- DFPP
- Shockwave
- IV Drip
Umbilical cord mesenchymal stem cell (UC-MSC) therapy for autoimmune disease is offered in Thailand, mostly in Bangkok, but it is still investigational and, under Thai rules, should only be given within an approved research protocol. The strongest evidence is for lupus that has not responded to standard drugs, and it is much weaker for most other conditions. This guide covers who may benefit, which tests to bring, how the cells are given, what a 1 to 3 week stay looks like, and the costs and risks, with an honest evidence level for each condition.
Only within approved research. Thailand allows routine stem cell treatment for a short list of blood disorders, such as leukaemia, lymphoma, aplastic anaemia and thalassemia. Other uses, including autoimmune disease, must go through a research protocol approved by the Medical Council of Thailand and the hospital’s ethics committee, run by licensed doctors at approved institutions. Thai officials have said that stem cell injections outside those permitted uses, when openly advertised by clinics, are illegal (The Nation, Oct 2024).
The rules are also tightening. A recent Ministry of Public Health decree under the Drug Act classifies expanded cells such as MSCs as Advanced Therapy Medicinal Products. These must be made in GMP facilities (PIC/S standard) and registered with the Thai FDA (The Nation, May 2026).
Most providers are in Bangkok. Before you book, ask the clinic for:
A clinic that cannot show these, or that promises a cure, is a warning sign.
| 📌 If you’re planning treatment in Thailand and want a practical checklist for choosing a safe clinic, we have an interesting article that discusses whether stem cell therapy is safe in Thailand, which you can read via the internal link. |
Note to editor: before publishing, add your clinic’s own protocol approval and lab licence details here. Thai authorities prosecute exaggerated stem cell advertising, so every claim on this page should match what your approval covers.
The people studied most are adults whose disease stays active despite standard treatment. In the lupus trials, for example, patients had active disease after at least 6 months of drugs such as cyclophosphamide or mycophenolate (Wang et al., 2014).
You may be a candidate if:
You are usually not a candidate if you have an uncontrolled infection, active cancer, severe heart failure, failure of a vital organ, or are pregnant or breastfeeding. These were exclusion criteria in the lupus trial above.
Bring recent results (ideally from the last 3 months) so the medical team can confirm your diagnosis, measure disease activity and screen for risks.
| Test | Why it is needed |
| Specialist letter and current medication list | Confirms diagnosis, doses of steroids and immunosuppressants |
| Complete blood count, liver and kidney function | Baseline safety check |
| Disease markers (e.g. ANA, anti-dsDNA, complement C3/C4 for lupus; thyroid antibodies for Hashimoto’s) | Measures activity and tracks response |
| Urine protein (24-hour or protein/creatinine ratio) | Needed if you have kidney involvement |
| Infection screen: hepatitis B and C, HIV, tuberculosis | Cell therapy and immunosuppressants can reactivate infections |
| MRI brain and spine (recent) | Needed for multiple sclerosis |
| Chest X-ray, ECG | General fitness for treatment |
| Cancer screening appropriate for your age | Active cancer is an exclusion |
The clinic may repeat some tests on arrival.
Most programmes follow the same five steps. Your clinic’s protocol may differ, so ask for a written day-by-day plan before you travel.
Plan for a stay of 1 to 3 weeks in Bangkok. A single IV course may need about 1 week. Two doses a week apart, or an intrathecal dose for multiple sclerosis with extra observation, usually needs 2 to 3 weeks.
| 📌 If you’re interested in whether a second dose can extend the benefits of the first, we have an interesting article that discusses why double-dose UC-MSC therapy may offer greater benefits than a single dose, which you can read via the internal link. |
The effect takes longer than the stay. In lupus studies, changes in disease scores and kidney markers were measured over 3 to 12 months. Some patients relapsed after 6 months, and the researchers suggested a repeat infusion may be needed (Wang et al., 2014). Ask your clinic up front whether a second course is likely, and what it costs.
The route depends on where the disease is. Most autoimmune conditions affect the whole body, so the cells are given intravenously. Intrathecal injection is mainly studied for multiple sclerosis, because it puts cells directly into the fluid around the brain and spinal cord.
| Route | How it is given | Mainly studied for | Main risks |
| Intravenous (IV) | Drip into a vein over 30 to 60 minutes | Lupus, psoriasis, most systemic conditions | Fever, headache, infusion reaction |
| Intrathecal | Lumbar puncture into spinal fluid | Multiple sclerosis | Headache, back pain, local inflammatory reaction |
| Local injection | Into a joint, skin lesion or affected tissue | Joint or skin involvement | Pain, swelling at the site |
Evidence is mixed. In a 48-patient randomized, sham-controlled trial in progressive MS, both routes reduced treatment failure compared with sham, and intrathecal did better than IV on several measures (Petrou et al., 2020). However, a later Norwegian placebo-controlled trial found no regenerative effect from a single intrathecal dose and saw local inflammatory reactions, and advised caution (SMART-MS). Both trials used patients’ own bone marrow MSCs, not cord cells.
Evidence differs a lot by condition. None of these uses is an approved standard treatment, and no study has shown a cure.
| Condition | Evidence level | Best available studies |
| Lupus (SLE), treatment-resistant | Low to moderate | Open-label multicentre study (40 patients); one small placebo-controlled trial found no added benefit |
| Multiple sclerosis, progressive | Low to moderate | Randomized trials of bone marrow MSCs with mixed results; little data on cord cells |
| Psoriasis, moderate to severe | Low | One single-arm study of 17 patients |
| Hashimoto’s thyroiditis | Very low | Animal and laboratory studies only; no published human trials found |
Evidence level: Moderate = randomized controlled trials with consistent results. Low = small or uncontrolled studies. Very low = no human trials.
Lupus has the most research. In a multicentre study of 40 patients with active, treatment-resistant lupus, UC-MSCs were given by IV on days 0 and 7. They were well tolerated, with no transplant-related adverse events, and disease activity scores and kidney protein levels improved over 12 months. Several patients relapsed after 6 months (Wang et al., 2014).
That study had no control group. When a small randomized, placebo-controlled trial tested UC-MSCs on top of standard drugs for lupus nephritis, remission rates were similar in both groups, and the trial was stopped early (Deng et al., 2017). A French phase 1/2 trial, Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord, is testing IV doses of 1, 2 and 4 million cells per kg for safety.
Bottom line: UC-MSCs may help some people with lupus that resists standard drugs, but this has not been confirmed in controlled trials.
| 📌 If you’re interested in how MSCs calm overactive immune cells throughout the body, we have an interesting article that discusses mesenchymal stem cell therapy for immune modulation, which you can read via the internal link. |
The best MS data come from bone marrow MSCs, not cord cells. A 48-patient double-blind trial reported fewer treatment failures with MSCs than sham, especially in active disease (Petrou et al., 2020). A later trial of a single intrathecal dose found no regenerative benefit. Whether cord cells work the same way is unknown.
In a phase 1/2a study of 17 patients given IV UC-MSCs, no obvious side effects were seen over 6 months. About half (8 of 17) improved their psoriasis score by at least 40%, and 3 had little or no remaining disease (Cheng et al., 2022). With no comparison group, these results are early.
MSCs reduced thyroid inflammation and antibody levels in rats, but we found no published human trials. Hashimoto’s is usually well controlled with daily thyroid hormone. Stem cell therapy for it should only be offered in a registered trial.
Rheumatoid arthritis, Crohn’s disease and NK cell therapy are covered on their own pages:
Note to editor: replace the # links with your page URLs. Link to the main science article, “UC-MSC stem cell therapy for autoimmune diseases”, from this section too.
Not on your own, and not right away. In the lupus studies, patients stayed on their usual medicines, and any reduction was decided by their doctors based on test results (Wang et al., 2014). Stopping steroids suddenly can cause a dangerous adrenal crisis, and stopping other drugs can trigger a flare.
If your disease improves over the following months, your own rheumatologist or neurologist may lower doses step by step. Plan for this to be decided at home, with regular blood tests, not during your stay in Thailand.
In published studies, UC-MSC infusions have generally been well tolerated. Common short-term side effects include:
Serious problems are uncommon but possible. In the small placebo-controlled lupus trial, one patient in the stem cell group developed pneumonia and an abscess, and another died of severe pneumonia (Deng et al., 2017). People with autoimmune disease on immunosuppressants already have a higher infection risk, so screening and monitoring matter.
Long-term risks, beyond a few years, are not well known.
In Thailand, the biggest safety factor is choosing a legitimate provider. Check that the treatment runs under an approved protocol, that cells come from a GMP-certified laboratory, and that a specialist is in charge (see the clinic checklist above).
Prices vary widely between providers. The main factors are:
Insurance rarely covers investigational cell therapy. Ask for a written quote that lists cell dose, number of treatments, tests, doctor fees, hospital stay and follow-up, so you can compare providers fairly.
Note to editor: add your clinic’s actual price range here (for example, a starting price per IV course). Do not compare with prices in other countries unless you can cite a source.
Not sure if you are a candidate? Send us your specialist’s letter, current medication list and recent blood tests via WhatsApp or our consultation form. Our doctors will tell you whether your condition fits an approved protocol, what the evidence says for your disease, and what a realistic plan and budget look like, including when stem cell therapy is not the right choice.
This article is for general information. It does not replace advice from your own doctor. Do not change or stop any medicine without your doctor’s guidance.